Assessing Whether Moderna (MRNA) Is Undervalued As Growth Plans Face Profitability Test

Simply Wall St.03-24

AdvertisementModerna’s recent performance snapshot Moderna (MRNA) has drawn attention after a period of mixed returns, with the stock showing a loss over the past 3 years but a gain over the past year...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621095064?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/128680956-main-header/1756229826628","is_english":true,"pubTime":"2026-03-24 22:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621095064","market":"hk","top_or_hot":-1,"title":"Assessing Whether Moderna (MRNA) Is Undervalued As Growth Plans Face Profitability Test","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementModerna’s recent performance snapshot Moderna (MRNA) has drawn attention after a period of mixed returns, with the stock showing a loss over the past 3 years but a gain over the past year...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/assessing-whether-moderna-mrna-is-undervalued-as-growth-plan\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Whether Moderna (MRNA) Is Undervalued As Growth Plans Face Profitability Test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Whether Moderna (MRNA) Is Undervalued As Growth Plans Face Profitability Test\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-24 22:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/assessing-whether-moderna-mrna-is-undervalued-as-growth-plan><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementModerna’s recent performance snapshot Moderna (MRNA) has drawn attention after a period of mixed returns, with the stock showing a loss over the past 3 years but a gain over the past year...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/assessing-whether-moderna-mrna-is-undervalued-as-growth-plan\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/assessing-whether-moderna-mrna-is-undervalued-as-growth-plan","article_id":"2621095064","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/128680956-main-header/1756229826628"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/assessing-whether-moderna-mrna-is-undervalued-as-growth-plan","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621095064","pubTimestamp":1774361034,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Moderna’s recent performance snapshot\nModerna (MRNA) has drawn attention after a period of mixed returns, with the stock showing a loss over the past 3 years but a gain over the past year and year to date.\nSee our latest analysis for Moderna.\nDespite a small 1-day share price return decline of 0.19%, Moderna’s 90-day share price return of 58.81% and 1-year total shareholder return of 50.07% point to building momentum after a weak 3-year total shareholder return of 65.43%.\nIf you are looking...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4532":"文艺复兴科技持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","MRNA":"Moderna, Inc.","MRNX":"Defiance Daily Target 2X Long MRNA ETF","BK4585":"ETF&股票定投概念","BK4551":"寇图资本持仓","BK4501":"段永平概念","MRNY":"MRNA期权收益策略ETF-YieldMax","BK4568":"美国抗疫概念","BK4588":"碎股","BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓"},"translate_title":"随着增长计划面临盈利能力测试，评估Moderna(MRNA)是否被低估","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":1.5,"MRNX":0.6,"MRNY":0.6},"content_text":"AdvertisementModerna’s recent performance snapshot Moderna (MRNA) has drawn attention after a period of mixed returns, with the stock showing a loss over the past 3 years but a gain over the past year and year to date. See our latest analysis for Moderna. Despite a small 1-day share price return decline of 0.19%, Moderna’s 90-day share price return of 58.81% and 1-year total shareholder return of 50.07% point to building momentum after a weak 3-year total shareholder return of 65.43%. If you are looking beyond Moderna, this could be a good moment to scan for other healthcare names using our screener of 36 healthcare AI stocks. With Moderna reporting US$1.9b in revenue, a net loss of US$2.8b and a share price near US$51, the key question is simple: is this pricing in future growth, or could it still be a buying opportunity? Most Popular Narrative: 70.7% Undervalued With Moderna last closing at $51.28 and the narrative fair value set at $175, the gap between price and narrative expectations is wide and hard to ignore.  Despite the defunding of US governmental research and health services, Moderna remains in a commanding fundamental position. The company that made its name during the COVID-19 pandemic developing and manufacturing vaccines for the disease at breakneck pace also happened to have bagged a historic windfall in exchange for its performance. Less well-known is how Moderna reinvested the windfall in the wake of its success. The company has spent years plowing its profits into new innovations while maintaining a relatively pristine balance sheet for a company as large as it is. In biotech it is not uncommon for companies to keep low levels of debt. Moderna is unique among its peers for its particularly low valuation relative to its assets. Currently, the company is trading below its book value, with the potential for explosive growth depending on how any one of its numerous drug and treatment investments pan out. Even without any additional investment in medical innovation, the company has a lot of products in its pipeline ready to go.  Read the complete narrative. The narrative, according to woodworthfund, leans heavily on reinvested pandemic windfalls, a sizeable pipeline and a valuation framework built around future margins and cash generation rather than today's losses. Result: Fair Value of $175 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on a crowded drug pipeline turning into real revenue, and on Moderna moving from a US$2.8b loss toward sustained profitability before investor patience fades. Find out about the key risks to this Moderna narrative. Another view: market ratios flash a warning That $175 fair value narrative sits awkwardly beside the current market ratios. Moderna trades on a P/S of 10.5x, roughly in line with the US Biotechs average of 10.6x but far above its fair ratio of 1.3x, which points to meaningful valuation risk if sentiment cools. For a closer look at how this ratio gap could matter for investors, See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:MRNA P/S Ratio as at Mar 2026Next Steps With the story split between optimism and caution, this is a good time to look through the numbers yourself and decide what really matters here. You can start with 1 key reward and 1 important warning sign Looking for more investment ideas? If Moderna caught your eye, do not stop here. Use the Simply Wall St screener to spot other opportunities that could fit your style before they move.  Target dependable cash generators and income potential with our pick of 12 dividend fortresses built for investors who value regular payouts alongside stability. Hunt for quality at attractive prices by scanning through 55 high quality undervalued stocks that combine solid fundamentals with compelling valuations. Prioritise peace of mind by focusing on 74 resilient stocks with low risk scores designed to keep overall portfolio volatility in check.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621095064","isCrawlerRequest":true}